A Case of Progressive Multifocal Leukoencephalopathy in a Fumaric Acid-Treated Psoriasis Patient With Severe Lymphopenia Among Other Risk Factors.
carcinoma
fumaric acid esters
progressive multifocal leukoencephalopathy
psoriasis
Journal
Journal of central nervous system disease
ISSN: 1179-5735
Titre abrégé: J Cent Nerv Syst Dis
Pays: United States
ID NLM: 101595026
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
7
1
2022
pubmed:
8
1
2022
medline:
8
1
2022
Statut:
epublish
Résumé
Progressive multifocal leukoencephalopathy (PML) is a potentially fatal condition caused by a brain infection with JC polyomavirus (JCV), which occurs almost exclusively in immunocompromised patients. Modern immunosuppressive and immunomodulatory treatments for cancers and autoimmune diseases have been accompanied by increasing numbers of PML cases. We report a psoriasis patient treated with fumaric acid esters (FAEs) with concomitant hypopharyngeal carcinoma and chronic alcohol abuse who developed PML. Grade 4 lymphopenia at the time point of PML diagnosis suggested an immunocompromised state. This case underscores the importance of immune cell monitoring in patients treated with FAEs, even more so in the presence of additional risk factors for an immune dysfunction.
Identifiants
pubmed: 34992484
doi: 10.1177/11795735211037798
pii: 10.1177_11795735211037798
pmc: PMC8725211
doi:
Types de publication
Case Reports
Langues
eng
Pagination
11795735211037798Informations de copyright
© The Author(s) 2021.
Déclaration de conflit d'intérêts
Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
J Dtsch Dermatol Ges. 2020 Apr;18(4):367-368
pubmed: 32147940
J Neurovirol. 2016 Oct;22(5):683-687
pubmed: 27273076
N Engl J Med. 2013 Apr 25;368(17):1658-9
pubmed: 23614604
N Engl J Med. 2019 Apr 25;380(17):1676-1677
pubmed: 30969507
Neurol Neuroimmunol Neuroinflamm. 2021 Apr 26;8(4):
pubmed: 33903203
N Engl J Med. 2013 Apr 25;368(17):1657-8
pubmed: 23614603
Neurology. 2011 Sep 13;77(11):1061-7
pubmed: 21832229
PLoS One. 2013 Sep 20;8(9):e75091
pubmed: 24073237
J Neurovirol. 2013 Aug;19(4):351-8
pubmed: 23733308
Neurol Neuroimmunol Neuroinflamm. 2015 Mar 12;2(3):e85
pubmed: 25798449
N Engl J Med. 2019 Apr 25;380(17):1674-1676
pubmed: 30969500
Ann Neurol. 2015 Oct;78(4):501-14
pubmed: 26150206
Neurology. 2019 May 7;92(19):e2232-e2239
pubmed: 30952796
Science. 2004 Nov 19;306(5700):1380-3
pubmed: 15550673
Neurol Neuroimmunol Neuroinflamm. 2019 Oct 9;6(6):e628
pubmed: 31597693
Emerg Infect Dis. 2018 Aug;24(8):1594-1596
pubmed: 30016251
J Eur Acad Dermatol Venereol. 2015 Dec;29(12):2277-94
pubmed: 26481193
J Neurovirol. 2019 Apr;25(2):284-287
pubmed: 30864100
N Engl J Med. 2019 Apr 25;380(17):1597-1605
pubmed: 30969503
Nat Rev Neurol. 2021 Jan;17(1):37-51
pubmed: 33219338
BMC Neurol. 2015 Jul 08;15:108
pubmed: 26152311
Ann Clin Transl Neurol. 2019 Apr 08;6(5):923-931
pubmed: 31139690
N Engl J Med. 2013 Sep 12;369(11):1081
pubmed: 24024862
J Neurol. 2017 Jun;264(6):1155-1164
pubmed: 28536921
Gastroenterol Clin Biol. 2010 Apr-May;34(4-5):336-8
pubmed: 20547019
J Neurol. 2014 May;261(5):1021-4
pubmed: 24638202
J Neurol Neurosurg Psychiatry. 2010 Mar;81(3):247-54
pubmed: 19828476
Mult Scler J Exp Transl Clin. 2015 Jan-Dec;1:
pubmed: 26550483
N Engl J Med. 2013 Apr 25;368(17):1659-61
pubmed: 23614605
Antimicrob Agents Chemother. 2009 May;53(5):1840-9
pubmed: 19258267
N Engl J Med. 2015 Apr 9;372(15):1474-6
pubmed: 25853764
Neurol Neuroimmunol Neuroinflamm. 2019 Oct 9;6(6):e627
pubmed: 31597692
Ann Neurol. 2019 Apr;85(4):606-610
pubmed: 30761586